We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Aduhelm’s long and tortuous developmental pathway appears to have hit its final, insurmountable obstacle, with developer Biogen officially abandoning the first-ever-approved antiamyloid antibody for the treatment of Alzheimer’s disease (AD). Read More
National Cancer Institute (NCI)-designated centers are marking up oncology drugs by as much as 633 percent over the acquisition cost, according to a new cost analysis. Read More
GlaxoSmithKline is buying Sierra Oncology and its investigational cancer drug momelotinib in a $1.9 billion windfall for the San Mateo, Calif.- based biopharmaceutical company. Read More